Karen Waetjen
Karen Waetjen is director, GCP/GLP Compliance, Amgen.
Articles
Collaborative Efforts Address Key Data Integrity Challenges
Ganapathy Mohan;Christopher Turner ;Dennis O’Connor ;Lisa Fink ;Thomas Purdue ;Jeffrey Beebie;Kerri Robles ;Karen Waetjen
March 16th 2021Maintaining a quality culture across the diverse functions in a bio/pharmaceutical company is difficult. Representatives of the Quality Coordinating Committee of IQ Consortium report on collaborative efforts to address data integrity and the modernization of FDA’s good laboratory practice regulations.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: October 28th 2024 | Updated: November 22nd 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 15th 2024 | Updated: November 22nd 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 22nd 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 22nd 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
